BioLife Solutions, Inc.

NasdaqCM:BLFS

Sector

🏥 Health Care

Industries

🧬 Biotechnology

Location

United States

Market Cap

USD 1.02 B

Share Price

USD 21.48

Avg Daily Volume

551,968

Change (1 day)

0.52%

Change (1 year)

-0.05%

Change (YTD)

-17.26%

BioLife Solutions, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2025

BioLife Solutions, Inc. Gross Profit Margin is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

BioLife Solutions, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 31.64%, a -7.90% change year over year.
BioLife Solutions, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 34.36%, a 18.33% change year over year.
BioLife Solutions, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 29.04%, a -47.42% change year over year.
BioLife Solutions, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 55.23%, a -15.19% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Gross Profit Margin	EBIT Margin	EBITDA Margin	Net Income Margin

NasdaqCM: BLFS

BioLife Solutions, Inc.

CEO	Mr. Roderick de Greef
IPO Date	Nov. 22, 1989
Location	United States
Headquarters	3303 Monte Villa Parkway
Employees	159
Sector	🏥 Health Care
Industries Biotechnology

Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.